• Blog
  • Plasmid DNA Manufacturing Market Analysis

    Plasmid DNA Manufacturing Market Analysis

    Plasmid DNA Manufacturing Market Analysis
    Report code - SR1415 Delivery - 2 Weeks
    Get Free Sample |
    Plasmid DNA Manufacturing Market Size, Share, Trend, Forecast, Competitive Analysis, and G See more...

    Market Insights

    The Plasmid DNA Manufacturing Market was estimated to grow from USD 461.75 million in 2021 to USD 1137.98 million by 2028 at a healthy CAGR of 13.69% during the forecast period.

    Wish to get a free sample? Register Here.

     

    What is Plasmid DNA?

    Plasmid DNA plays a vital role in the modern healthcare industry. It can be utilized directly for therapeutic purposes, such as gene therapy or the production of vaccine antigens, or indirectly for a variety of research purposes such as gene mapping, gene cloning, etc. for preventing diseases like cystic fibrosis or Huntington’s disease. These include the usage of plasmid DNA as a vital starting material for temporary transfection to build viral-vector constructions like lentivirus or Adeno-associated virus (AAV) as well as transitory proteins in development like monoclonal antibodies. Gene therapy is a rapidly growing field in medicine that promises novel therapies for individuals suffering from a variety of ailments.

    Market Dynamics

    The global biopharmaceutical industry has seen growth in the plasmid DNA manufacturing business. The rising use of plasmid DNA in the biopharmaceutical industry for producing vaccines and treatments for a variety of ailments is driving up demand for plasmid DNA.

    Get the full scope of the report, Register Here.

    Key Players

    The following are the key players in the plasmid DNA manufacturing market:

    • Aldevron, LLC
    • Cell and Gene Therapy Catapult
    • Cobra Biologics and Pharmaceutical Services
    • Delphi Genetics
    • Eurofins Genomics
    • Kaneka Corporation
    • Nature Technology Corporation
    • PlasmidFactory GmbH and Co. KG
    • VGXI, Inc.
    • Waisman Biomanufacturing

    Segment Analysis

    Application Type

    The market is segmented as gene therapy, DNA vaccines, immunotherapy, and others. Gene therapy is projected to remain the dominant application of the market over the next five years owing to the increasing use of gene therapy to treat a variety of viral and genetic diseases. It is also widely used to diagnose disorders in patients, hence, increasing demand for the treatment. 

    Product Type

    The market is segmented as viral vectors, plasmid DNA, non-viral, electroporation, lipid/polymer, nanoparticles, and others. The viral vector is expected to remain the dominant as well as the fastest-growing product type in the market during the forecast period. The viral vector is already in high demand in the manufacturing of vaccines, cell treatments, and gene therapies all around the world. The COVID-19 pandemic contributed to the increased need for vaccine manufacture. Increasing preference for viral vectors for vaccines productions and various gene and immunotherapy applications is the major driving factor for the segment in the coming years.

    Regional Analysis

    North America is expected to remain the largest market for plasmid DNA manufacturing market during the forecast period. The rising number of contract manufacturers in the region is a result of increased investments in the development of new biopharmaceutical drugs. Furthermore, the USA holds the most intellectual property copyrights for most newly developed treatments. A key factor that is driving the demand for the plasmid DNA manufacturing market in North America is the increased adoption rate of modern healthcare services along with the growing preference for gene and cell therapies.

    Know which region offers the best growth opportunities, Register Here.

    Market Segmentation

    This report studies the market covering a period of 12 years of trend and forecast. The report provides detailed insights into the market dynamics to enable informed business decision-making and growth strategy formulation based on the opportunities present in the market.

    Report – Features

    Market Segmentation

    4

    Regions Covered

    4

    Countries/Sub-Regions Covered

    14

    No. of Figures & Tables

    >150

    Company Profiles

    10

    The market is segmented into the following categories. 

    By Product Type

    • Viral Vectors
    • Plasmid DNA
    • Non-Viral
    • Electroporation
    • Lipid/Polymer
    • Nanoparticles
    • Others

    By Application Type

    • Gene Therapy
    • DNA Vaccines
    • Immunotherapy
    • Others

    By Disease Type

    • Infectious Disease
    • Genetic Disorder
    • Cancer

    By Region

    • North America
    • Asia-Pacific
    • Europe 
    • Rest of the World

    Want to get more details about the segmentations, Click here.

    COVID-19 Impact

    Due to the COVID-19 pandemic, manufacturers of plasmid DNA are experiencing substantial challenges on multiple fronts. The supply of raw materials for producing medication formulations is a serious concern because of transportation facility inconsistences. Furthermore, due to an increase in the number of patients suffering from COVID-19 and other life-threatening conditions, distributors are seeing erratic demand for health-related products from retailers.

    Critical questions answered in the report-

    • What are the key trends in the market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
    • What is the impact of COVID-19 on the market?
    • What are the key strategies adopted by the major vendors to lead in the market?
    • What is the market share of the top vendors?

    Target Audience

    Here is the list of the group of customers that the plasmid DNA manufacturing market hopes to have the greatest opportunity to convert-

    • Distributors
    • Suppliers
    • Manufacturers
    • Logistics organizations
    • Government bodies

    Report Features

    This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market. The following are the key features of the report:

    • Overview, industry life cycle analysis, supply chain analysis.
    • Environment analysis: Growth drivers and constraints, Porter’s five forces analysis, SWOT analysis.
    • Trend and forecast analysis.
    • Segment trend and forecast.
    • Competitive landscape and dynamics: Market share, Product portfolio, New Product Launches, etc.
    • Attractive market segments and associated growth opportunities.
    • Emerging trends.
    • Strategic growth opportunities for the existing and new players.
    • Key success factors.

    Plasmid DNA Manufacturing Market Features

    Market Size in 2028

    USD 1,137.98 million

    Market Size in 2021

    USD 461.75 million

    Market Growth (2022-2028)

    13.69% CAGR

    Base Year of Study

    2021

    Trend Period

    2016-2020

    Forecast Period

    2022-2028

    Segments Covered

    By Product Type (Viral Vectors, Plasmid DNA, Non-Viral, Electroporation, Lipid/Polymer, Nanoparticles, and Others)

    By Application (Gene Therapy, DNA Vaccines, Immunotherapy, and Others)

    By Disease Type (Infectious Disease, Genetic Disorder, and Cancer)

    By Region (North America, Asia-Pacific, Europe, and the Rest of the World)

    Top Companies in 2022

    • Aldevron, LLC
    • Cell and Gene Therapy Catapult
    • Cobra Biologics and Pharmaceutical Services
    • Delphi Genetics
    • Eurofins Genomics
    • Kaneka Corporation
    • Nature Technology Corporation
    • PlasmidFactory GmbH and Co. KG
    • VGXI, Inc.
    • Waisman Biomanufacturing

    Dominant Region

    The North American market accounted for the largest market share in 2021.

    Research Methodology

    This strategic assessment report, from Stratview Research, provides a comprehensive analysis that reflects today’s market realities and future market possibilities for the forecast period of 2022 to 2028.

    The report segments and analyzes the market in the most detailed manner in order to provide a panoramic view of the market.

    The vital data/information provided in the report can play a crucial role for the market participants as well as investors in the identification of the low-hanging fruits available in the market as well as to formulate the growth strategies to expedite their growth process.

    This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. 

    More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data. 

    We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

    Report Customization

    With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

    Company Profiling

    • Detailed profiling of additional market players (up to three players)
    • SWOT analysis of key players (up to three players)

    Competitive Benchmarking

    • Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.

    Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at sales@stratviewresearch.com.

    Frequently Asked Questions (FAQs)

    Plasmid DNA plays a vital role in the modern healthcare industry. It can be utilized directly for therapeutic purposes, such as gene therapy or the production of vaccine antigens, or indirectly for a variety of research purposes such as gene mapping, gene cloning, etc. for preventing diseases like cystic fibrosis or Huntingtons disease. These include the usage of plasmid DNA as a vital starting material for temporary transfection to build viral-vector constructions like lentivirus or Adeno-associated virus (AAV) as well as transitory proteins in development like monoclonal antibodies. Gene therapy is a rapidly growing field in medicine that promises novel therapies for individuals suffering from a variety of ailments.

    The plasmid DNA manufacturing market was estimated to grow from USD 461.75 million in 2021 to USD 1137.98 million by 2028.

    Aldevron, LLC, Cell and Gene Therapy Catapult, Cobra Biologics and Pharmaceutical Services, Delphi Genetics, Eurofins Genomics, Kaneka Corporation, Nature Technology Corporation, PlasmidFactory GmbH and Co. KG, VGXI, Inc., Waisman Biomanufacturing.

    The plasmid DNA manufacturing market is expected to witness an impressive growth of 13.69% CAGR in the coming years.

    The North American market accounted for the largest market share in 2021.

    The global biopharmaceutical industry has seen growth in the plasmid DNA manufacturing business. The rising use of plasmid DNA in the biopharmaceutical industry for producing vaccines and treatments for a variety of ailments is driving up demand for plasmid DNA.

    Gene therapy is projected to remain the dominant application in the market.

    By Product Type (Viral Vectors, Plasmid DNA, Non-Viral, Electroporation, Lipid/Polymer, Nanoparticles, and Others), by Application (Gene Therapy, DNA Vaccines, Immunotherapy, and Others), by Disease Type (Infectious Disease, Genetic Disorder, and Cancer), and by Region (North America, Europe, Asia-Pacific, and Rest of the World).

    •   
    ×